awgldk
/
wikidata
/
Login
Register
TriplyDB
Wikidata
Browser
Table
SPARQL
Graphs
1
1
Services
1
1
Assets
0
0
Insights
Schema
BETA
Class frequency
Class hierarchy
Q38062022-916C8A05-6F79-406E-AA48-09EB65C6D07E
Q38062022-916C8A05-6F79-406E-AA48-09EB65C6D07E
BestRank
Statement
http://www.wikidata.org/entity/statement/Q38062022-916C8A05-6F79-406E-AA48-09EB65C6D07E
Pathways and targets in hepatocellular carcinoma.
P2860
Q38062022-916C8A05-6F79-406E-AA48-09EB65C6D07E
BestRank
Statement
http://www.wikidata.org/entity/statement/Q38062022-916C8A05-6F79-406E-AA48-09EB65C6D07E
rank
NormalRank
type
BestRank
Statement
wasDerivedFrom
66cc42e0d64f5b4a0312e21e0a5160c18cb9ef73
P2860
Phase II, open-label study of brivanib as second-line therapy in patients with advanced hepatocellular carcinoma.